Virtus Investment Advisers, Inc. Bei Gene, Ltd. Transaction History
Virtus Investment Advisers, Inc.
- $289 Million
- Q1 2025
A detailed history of Virtus Investment Advisers, Inc. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Virtus Investment Advisers, Inc. holds 1,989 shares of BGNE stock, worth $450,926. This represents 0.16% of its overall portfolio holdings.
Number of Shares
1,989Holding current value
$450,926% of portfolio
0.16%Shares
1 transactions
Others Institutions Holding BGNE
# of Institutions
290Shares Held
40MCall Options Held
111KPut Options Held
112K-
Baker Bros. Advisors LP New York, NY8.8MShares$1.99 Billion23.78% of portfolio
-
Capital International Investors Los Angeles, CA5.09MShares$1.15 Billion0.24% of portfolio
-
Primecap Management CO Pasadena, CA5.06MShares$1.15 Billion0.97% of portfolio
-
Baillie Gifford & CO3.63MShares$823 Million0.74% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.71MShares$615 Million0.09% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...